Finasteride 1 mg Reviews vs Proscar 5 mg: Hair Line, Prostate Line

Do not mix the 1 mg ledger with the 5 mg ledger

Claim on the board: one vanity hair pill accidentally shrinks prostates. Label the record instead as two randomised programs that never shared a dose or a primary endpoint.

Finasteride blocks type 2 5-alpha-reductase and drops circulating DHT by about 65 percent. DHT enlarges prostate tissue and miniaturises balding follicles, so cutting it hits both organs. That is the whole mechanism. Everything below is arithmetic on that fact. Hair evidence uses 1 mg daily in men 18 to 41 with early thinning. Prostate evidence uses 5 mg daily in older men with enlarged glands. Swapping those numbers is the commonest error in 'reviews' of this drug.

Score each line on its own endpoints. The 1 mg line really slows visible loss and modestly thickens some crowns. The 5 mg line really cuts acute retention and prostate surgery over years. Effect sizes are steady, not cinematic. The tablet only works while you swallow it. How both uses sprang from one genetic observation is the 5-alpha history file. This page stays with what was measured.

Kaufman's circle: 107 hairs, then 138, then 277

The pivotal 1 mg program, published by Kaufman and colleagues in 1998, randomised 1,553 men with vertex-pattern loss to finasteride 1 mg or placebo for a year, then kept most of them in blinded extensions. Endpoints were blunt on purpose: hair counts in a 1-inch (5.1 cm2) circle, patient questionnaires, investigator grades, and a blinded photo panel. At 12 months the treated group sat 107 hairs above placebo in that circle. At two years the gap was 138. At five years, because placebo kept sliding, the gap reached 277 hairs.

Read those gaps as hold-plus-some, not a hairline reset. At one year, 14 percent of treated men had any further count loss versus 58 percent on placebo. Investigators called 65 percent of 1 mg men improved at 12 months versus 37 percent on placebo. The independent photo panel was harsher: 48 percent improved on drug versus 7 percent on placebo at one year. Crown and mid-scalp moved. Deep bitemporal recession was not the counted zone. A 12-month study in postmenopausal women showed no benefit. File the 1 mg promise as 'keep most of what you have, recover a little at the vertex.' Stop the tablet and the count advantage reverses within a year.

PLESS: retention and surgery, not a flow slogan

On the 5 mg line, symptom scores matter - but the endpoints men actually fear are a catheter for acute retention and an operation.

The Proscar Long-Term Efficacy and Safety Study followed 3,040 men with moderate to severe BPH symptoms for four years. Finasteride 5 mg cut the risk of acute urinary retention by 57 percent and the need for BPH-related surgery by 55 percent versus placebo. Median prostate volume fell about 18 percent. Men with genuinely large glands gained more, because there was more DHT-driven tissue to lose. Men with small glands and night walking from another cause often gained little. That size dependence is the clearest trial lesson on this line: 5 mg is therapy for enlargement, not for every man who wakes to urinate.

Flow and bother scores moved, but they moved slowly. Counsel that way. A 5 mg tablet is not an alpha-blocker. It will not relax smooth muscle in days. It shrinks tissue over months. If a man needs a fast stream change, another class does that job. If he needs fewer crises over years, this is the ledger that supports the claim.

MTOPS paired a shrinker with a relaxer

The Medical Therapy of Prostatic Symptoms trial enrolled 3,047 men and ran four to six years. It compared placebo, finasteride 5 mg, doxazosin (an alpha-blocker), and the pair. Combination reduced overall clinical progression more than either drug alone. Different clocks, one program: doxazosin relaxes prostatic smooth muscle within days; finasteride shrinks volume over months. That is why urologists still stack them in larger glands instead of pretending one tablet covers both tempos.

MTOPS also left a safety footnote the label still carries: four cases of male breast cancer in men who received finasteride, none in men who did not, in that study. PLESS had the opposite split - two cases on placebo, none on drug. PCPT had one case on each arm. The relationship between long-term finasteride and male breast neoplasia is listed as unknown. Report new breast lumps, pain, or nipple discharge. Do not turn a rare, unsettled signal into a slogan. Dosing that follows from these data sits in the 1 mg cost and honesty guide.

PCPT cut cancers and left a Gleason asterisk

The Prostate Cancer Prevention Trial randomised 18,882 men aged 55 or older with a normal rectal exam and PSA at or below 3.0 ng/mL to finasteride 5 mg or placebo for seven years, then biopsied. Overall prostate-cancer detection fell from 24.4 percent on placebo to 18.4 percent on drug - a 24.8 percent relative reduction. That is a real prevention signal for an inexpensive, familiar tablet. It is also not an approved indication. The US label says finasteride is not approved to prevent prostate cancer.

Then the asterisk that dominated headlines. Gleason 8 to 10 cancers were more common on finasteride (1.8 percent) than on placebo (1.1 percent). High-grade (Gleason 7 to 10) fractions ran 6.4 percent versus 5.1 percent. Dutasteride later showed a similar high-grade pattern. Years of argument followed: the drug shrinks glands and changes PSA, which can make biopsies and screening more sensitive to aggressive disease, so part of the excess may be detection, not causation. The question is not closed. I file it as written: real drop in total cancers, debated high-grade signal, and a reason nobody should swallow 5 mg as a cancer-prevention plan.

The half-cut PSA that rewrites a blood test

Even a man who never thinks about cancer needs this line: the tablet reshapes a marker clinicians use every week.

Prostate-specific antigen falls about 50 percent after six to twelve months on finasteride, because the gland makes less of it once volume drops. The shift is expected. It is dangerous only if nobody adjusts. A 'normal' number can hide a trend that would have triggered work-up on an untreated scale. The correction is automatic once you know it: roughly double the reported PSA before comparing to untreated ranges, and watch direction more than any single draw.

A rising PSA on therapy is the red flag, because the drug should be holding production down. Tell whoever orders the test. A cheap 1 mg hair tablet does this too, not only the 5 mg gland tablet. More on that trap - plus pregnancy handling and sexual-signal percents - sits in the 1 mg cost and honesty guide.

Score both lines, then stop shopping for a miracle

Stack the uses by data strength and by the kind of benefit you should expect. The pattern is obvious once the ledgers stay apart.

The table pairs each use with its best supporting evidence and a plain verdict. Approved indications are solid. Cancer prevention is real and hedged. None of the effect sizes are blockbuster-sized. That is the right tone for a drug this widely prescribed, including the generic 1 mg strips sold as hair reviews.

Finasteride, dutasteride, minoxidil are not twins

Dutasteride blocks type 1 and type 2 and suppresses DHT more completely - often over 90 percent versus about 65 to 70 percent for finasteride - with a much longer half-life. Stronger gland effect in some men. Same sexual-signal conversation, sometimes louder. Widely used for BPH. Often used off-label for hair. Minoxidil ignores DHT. It is thought to extend anagen and change local perfusion. It complements a 1 mg tablet rather than replacing it. Early shed on minoxidil is common and is not proof the plan failed.

Clinic read: 1 mg plus topical minoxidil covers two independent steps and is the usual medical backbone for male-pattern loss. Dutasteride is the heavier DHT hammer when 1 mg underperforms and a clinician is willing to use it off-label for hair. None is permanent. All need ongoing use. Sexual-signal honesty belongs in the consult, not in a cart blurb. Core pharmacology of the 1 mg tablet is on the Propecia 1 mg fact line.